These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22875602)

  • 1. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab.
    Shimizu M; Ueno K; Yachie A
    Clin Vaccine Immunol; 2012 Oct; 19(10):1700-2. PubMed ID: 22875602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.
    Shinoki T; Hara R; Kaneko U; Miyamae T; Imagawa T; Mori M; Yokota S
    Mod Rheumatol; 2012 Nov; 22(6):871-6. PubMed ID: 22322589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6.
    Shimizu M; Nakagishi Y; Kasai K; Yamasaki Y; Miyoshi M; Takei S; Yachie A
    Cytokine; 2012 May; 58(2):287-94. PubMed ID: 22398373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
    Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
    Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
    Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.
    Nozawa T; Nishimura K; Ohara A; Hara R; Ito S
    Mod Rheumatol; 2019 May; 29(3):558-562. PubMed ID: 27846755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
    Sakumura N; Shimizu M; Mizuta M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2018 Oct; 110():459-465. PubMed ID: 29801971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
    Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
    J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab for treating juvenile idiopathic arthritis.
    Turnier JL; Brunner HI
    Expert Opin Biol Ther; 2016; 16(4):559-66. PubMed ID: 26848760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.
    Fujieda M; Tsuruga K; Sato T; Kikuchi H; Tamaki W; Ishihara M; Yamamoto M; Oishi T; Tanaka H; Daibata M
    Mod Rheumatol; 2017 Jan; 27(1):66-71. PubMed ID: 27166661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
    Yasuoka R; Iwata N; Abe N; Kohagura T; Nakaseko H; Shimizu M; Kawabe S
    Mod Rheumatol; 2019 Mar; 29(2):324-327. PubMed ID: 29578355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay.
    Camacho-Lovillo MS; Bulnes-Ramos A; Goycochea-Valdivia W; Fernández-Silveira L; Núñez-Cuadros E; Neth O; Pérez-Romero P
    Pediatr Rheumatol Online J; 2017 Aug; 15(1):62. PubMed ID: 28784185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.